Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX vs Solifenacin in Overactive Bladder
NCT01767519Phase 3Completed
- Sponsor
- Allergan
- Start
- Mar 2013
- Primary completion
- Sep 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
A Phase 3 trial of onabotulinumtoxinA in overactive bladder (OAB), urinary incontinence (UI), sponsored by Allergan. Started Mar 2013; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
overactive bladder (OAB)urinary incontinence (UI)
Beyond the preview
Go deeper on NCT01767519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01767519.